Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11140MR)

This product GTTS-WQ11140MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Dermatomyositis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11140MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15948MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ10702MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ3729MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ12036MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ5856MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ2297MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ8656MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ1950MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS15C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW